Amalric Marianne
Aix-Marseille University, CNRS UMR 7291, Laboratoire de Neurosciences Cognitives (LNC), FR3C 3512, 13331 Marseille, France.
Curr Opin Pharmacol. 2015 Feb;20:29-34. doi: 10.1016/j.coph.2014.11.001. Epub 2014 Nov 19.
The interplay between dopamine and glutamate in the basal ganglia regulate critical aspects of motor and cognitive behavior. Metabotropic glutamate (mGlu) receptors are key modulators of glutamatergic dysfunction in Parkinson's disease (PD). Preclinical evidence demonstrate that group I mGlu receptor antagonism and groups II and III mGlu receptor activation improve motor symptomatology of PD and decrease l-DOPA-induced dyskinesia by regulating excitatory and inhibitory transmission in the basal ganglia. Emotional and cognitive deficits are also observed in PD. Treatment of these symptoms is challenging and underscore the need for novel effective and well tolerated pharmacological treatments. This article will thus review the currently available knowledge regarding the therapeutic potential of targeting mGlu receptors to restore motor and nonmotor symptoms of PD.
多巴胺与谷氨酸在基底神经节中的相互作用调节着运动和认知行为的关键方面。代谢型谷氨酸（mGlu）受体是帕金森病（PD）中谷氨酸能功能障碍的关键调节因子。临床前证据表明，I组mGlu受体拮抗以及II组和III组mGlu受体激活可通过调节基底神经节中的兴奋性和抑制性传递来改善PD的运动症状，并减少左旋多巴诱导的运动障碍。PD患者还存在情绪和认知缺陷。治疗这些症状具有挑战性，这突出了对新型有效且耐受性良好的药物治疗的需求。因此，本文将综述目前关于靶向mGlu受体以恢复PD运动和非运动症状的治疗潜力的现有知识。
